Barclays PLC lifted its holdings in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 127.4% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 361,036 shares of the company's stock after buying an additional 202,248 shares during the period. Barclays PLC owned 0.05% of ImmunityBio worth $1,344,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Victory Capital Management Inc. increased its position in ImmunityBio by 16.0% in the second quarter. Victory Capital Management Inc. now owns 19,953 shares of the company's stock worth $126,000 after buying an additional 2,746 shares during the period. Wealth Effects LLC grew its position in shares of ImmunityBio by 3.4% during the third quarter. Wealth Effects LLC now owns 90,500 shares of the company's stock worth $337,000 after acquiring an additional 3,000 shares during the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of ImmunityBio by 8.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 47,984 shares of the company's stock worth $178,000 after acquiring an additional 3,722 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in ImmunityBio by 22.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company's stock valued at $99,000 after purchasing an additional 4,545 shares during the last quarter. Finally, Courier Capital LLC boosted its stake in ImmunityBio by 50.0% during the 3rd quarter. Courier Capital LLC now owns 30,000 shares of the company's stock valued at $112,000 after purchasing an additional 10,000 shares during the period. Institutional investors and hedge funds own 8.58% of the company's stock.
Analysts Set New Price Targets
A number of brokerages recently issued reports on IBRX. D. Boral Capital reissued a "buy" rating and issued a $30.00 price objective on shares of ImmunityBio in a report on Friday, December 20th. EF Hutton Acquisition Co. I raised ImmunityBio to a "strong-buy" rating in a research note on Wednesday, October 23rd.
Read Our Latest Research Report on IBRX
ImmunityBio Stock Performance
Shares of IBRX stock traded up $0.09 during midday trading on Friday, reaching $2.78. 8,035,703 shares of the company were exchanged, compared to its average volume of 5,058,733. The company's 50 day moving average price is $4.40 and its two-hundred day moving average price is $4.61. The company has a market cap of $1.94 billion, a P/E ratio of -3.02 and a beta of 0.86. ImmunityBio, Inc. has a 12 month low of $2.50 and a 12 month high of $10.53.
ImmunityBio Company Profile
(
Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Featured Articles
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
